Finding 1148966 (2023-007)

Significant Deficiency Repeat Finding
Requirement
AB
Questioned Costs
-
Year
2023
Accepted
2025-08-05

AI Summary

  • Core Issue: Internal controls are inadequate for ensuring proper approval of costs under the COVID-19 funding program.
  • Impacted Requirements: All costs must receive formal approval to comply with federal guidelines.
  • Recommended Follow-Up: Management should strengthen internal controls to ensure all costs are formally approved moving forward.

Finding Text

2023‐007 Department of Treasury Federal Financial Assistance Listing/ALN 21.027 COVID‐19 Coronavirus State and Local Fiscal Recovery Funds Allowable Costs and Allowable Activities Significant Deficiency in Internal Control over Compliance Criteria ‐ A good system of internal controls includes a process to ensure that proper approvals are obtained relating to costs under the program. Condition ‐ We noted that the Organization’s internal controls did not have adequate internal controls to ensure costs are properly approved. Cause ‐ During the course of our engagement, we noted that two costs under the program were not formally approved. Effect ‐ The Organization’s internal controls failed to formally approve costs under the program. Questioned Costs ‐ None Reported. Context/Sampling ‐ A nonstatistical sample of 46 costs were selected for expense testing. 2 out of the 46 transactions did not have formal approval. These transactions totaled $400 of $3,274,092 costs tested. Recommendation ‐ Management should implement internal controls to ensure all costs under the program are formally approved. Views of Responsible Officials ‐ Management is in agreement with the finding. Repeat Finding – This is a repeat finding of 2022-006.

Categories

Allowable Costs / Cost Principles Significant Deficiency Internal Control / Segregation of Duties

Other Findings in this Audit

  • 572520 2023-006
    Material Weakness
  • 572521 2023-006
    Material Weakness
  • 572522 2023-006
    Material Weakness
  • 572523 2023-007
    Significant Deficiency Repeat
  • 572524 2023-007
    Significant Deficiency Repeat
  • 572525 2023-007
    Significant Deficiency Repeat
  • 572526 2023-008
    Material Weakness
  • 572527 2023-008
    Material Weakness
  • 572528 2023-008
    Material Weakness
  • 572529 2023-009
    Material Weakness Repeat
  • 572530 2023-009
    Material Weakness Repeat
  • 572531 2023-009
    Material Weakness Repeat
  • 572532 2023-010
    Material Weakness Repeat
  • 572533 2023-010
    Material Weakness Repeat
  • 572534 2023-010
    Material Weakness Repeat
  • 572535 2023-011
    Material Weakness
  • 572536 2023-011
    Material Weakness
  • 572537 2023-011
    Material Weakness
  • 1148962 2023-006
    Material Weakness
  • 1148963 2023-006
    Material Weakness
  • 1148964 2023-006
    Material Weakness
  • 1148965 2023-007
    Significant Deficiency Repeat
  • 1148967 2023-007
    Significant Deficiency Repeat
  • 1148968 2023-008
    Material Weakness
  • 1148969 2023-008
    Material Weakness
  • 1148970 2023-008
    Material Weakness
  • 1148971 2023-009
    Material Weakness Repeat
  • 1148972 2023-009
    Material Weakness Repeat
  • 1148973 2023-009
    Material Weakness Repeat
  • 1148974 2023-010
    Material Weakness Repeat
  • 1148975 2023-010
    Material Weakness Repeat
  • 1148976 2023-010
    Material Weakness Repeat
  • 1148977 2023-011
    Material Weakness
  • 1148978 2023-011
    Material Weakness
  • 1148979 2023-011
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
21.027 Coronavirus State and Local Fiscal Recovery Funds $150,000
14.267 Continuum of Care Program $147,558
97.024 Emergency Food and Shelter National Board Program $19,875
14.218 Community Development Block Grants/entitlement Grants $12,590
14.231 Emergency Solutions Grant Program $8,299